The New England journal of medicine, 2013-03, Vol.368 (12), p.1101-1110
- Friboulet, Luc
- Olaussen, Ken André
- Pignon, Jean-Pierre
- Shepherd, Frances A
- Tsao, Ming-Sound
- Graziano, Stephen
- Kratzke, Robert
- Douillard, Jean-Yves
- Seymour, Lesley
- Pirker, Robert
- Filipits, Martin
- André, Fabrice
- Solary, Eric
- Ponsonnailles, Florence
- Robin, Angélique
- Stoclin, Annabelle
- Dorvault, Nicolas
- Commo, Frédéric
- Adam, Julien
- Vanhecke, Elsa
- Saulnier, Patrick
- Thomale, Jürgen
- Le Chevalier, Thierry
- Dunant, Ariane
- Rousseau, Vanessa
- Le Teuff, Gwénaël
- Brambilla, Elisabeth
- Soria, Jean-Charles
2013
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Friboulet, Luc
- Olaussen, Ken André
- Pignon, Jean-Pierre
- Shepherd, Frances A
- Tsao, Ming-Sound
- Graziano, Stephen
- Kratzke, Robert
- Douillard, Jean-Yves
- Seymour, Lesley
- Pirker, Robert
- Filipits, Martin
- André, Fabrice
- Solary, Eric
- Ponsonnailles, Florence
- Robin, Angélique
- Stoclin, Annabelle
- Dorvault, Nicolas
- Commo, Frédéric
- Adam, Julien
- Vanhecke, Elsa
- Saulnier, Patrick
- Thomale, Jürgen
- Le Chevalier, Thierry
- Dunant, Ariane
- Rousseau, Vanessa
- Le Teuff, Gwénaël
- Brambilla, Elisabeth
- Soria, Jean-Charles
- Titel
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- Ist Teil von
- The New England journal of medicine, 2013-03, Vol.368 (12), p.1101-1110
- Ort / Verlag
- Waltham, MA: Massachusetts Medical Society
- Erscheinungsjahr
- 2013
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Earlier studies suggested that the response to platinum treatment in lung cancer might be predicted according to the presence or absence of the DNA repair enzyme ERCC1. This study shows that the available antibodies do not predict response because they may detect nonfunctional enzymes. In patients with resected stage IB, IIA or IIB, or IIIA non–small-cell lung cancer (NSCLC), platinum-based postoperative chemotherapy is now standard treatment, with an estimated increase in the survival rate of 4 to 5% at 5 years. 1 , 2 The identification of predictive biomarkers of the efficacy of adjuvant chemotherapy could lead to an improved therapeutic index. 3 DNA repair capacity is a major determinant of cisplatin resistance; in particular, the excision repair cross-complementation group 1 (ERCC1) protein plays an essential role in nucleotide excision repair. Together with its partner, xeroderma pigmentosum complementation group F (XPF), ERCC1 cleaves DNA structures near the . . .
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1214271Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4054818
- Format
- –
- Schlagworte
- Antibodies, Antineoplastic Agents - therapeutic use, Biological and medical sciences, Biomarkers, Biomarkers, Tumor - metabolism, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - genetics, Carcinoma, Non-Small-Cell Lung - mortality, Chemotherapy, Chemotherapy, Adjuvant, Cisplatin, Cisplatin - therapeutic use, Clinical decision making, Clinical trials, Decision making, Deoxyribonucleic acid, Discordance, DNA, DNA damage, DNA Repair, DNA, Neoplasm, DNA-Binding Proteins - genetics, DNA-Binding Proteins - immunology, DNA-Binding Proteins - metabolism, Drug Resistance, Neoplasm - genetics, Endonucleases - genetics, Endonucleases - immunology, Endonucleases - metabolism, Epitope Mapping, Epitopes, ERCC1 protein, General aspects, Humans, Immunoglobulin G, Isoforms, Kaplan-Meier Estimate, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - genetics, Lung Neoplasms - mortality, Lungs, Medical sciences, Non-small cell lung carcinoma, Nucleotide excision repair, Platinum, Pneumology, Protein Isoforms - genetics, Protein Isoforms - metabolism, Proteins, Tumors, Tumors of the respiratory system and mediastinum